Table 1.
Characteristics of included drugs. Nominal USD.
| Characteristic | Number (percent) |
|---|---|
| Unique drugs | 89 |
| Drug-year observations | 361 |
| Year of approval | |
| 1997 | 2 (2%) |
| 1998 | 2 (2%) |
| 2000 | 1 (1%) |
| 2002 | 2 (2%) |
| 2003 | 2 (2%) |
| 2004 | 3 (3%) |
| 2005 | 3 (3%) |
| 2006 | 5 (6%) |
| 2007 | 3 (3%) |
| 2008 | 2 (2%) |
| 2009 | 2 (2%) |
| 2010 | 3 (3%) |
| 2011 | 7 (8%) |
| 2012 | 11 (12%) |
| 2013 | 6 (7%) |
| 2014 | 8 (9%) |
| 2015 | 13 (15%) |
| 2016 | 5 (6%) |
| 2017 | 9 (10%) |
| Medicare coverage | |
| Part D | 48 (54%) |
| Part B | 40 (45%) |
| Both | 1 (1%) |
| Class | |
| Targeted agent | 50 (56%) |
| Cytotoxic | 12 (13%) |
| Monoclonal antibody | 9 (10%) |
| Immunotherapy | 7 (8%) |
| Other | 5 (6%) |
| Antibody conjugate | 3 (3%) |
| Hormonal agent | 3 (3%) |
| Unique physicians prescribing (median, IQR) | 1212 (364, 3358) |
| Industry payments per unique physician, USD (median, IQR) | 416 (120, 1,030) |
| Medicare spending per unique physician, USD (median, IQR) | 49 650 (34 015, 74 042) |
| Drug spending per drug (millions USD) | |
| 2014 | |
| <1 | 2 (4%) |
| 1-10 | 10 (20%) |
| >10-100 | 20 (39%) |
| >100-1000 | 18 (35%) |
| >1,000 | 1 (2%) |
| 2015 | |
| <1 | 4 (6%) |
| 1-10 | 12 (18%) |
| >10-100 | 27 (42%) |
| >100-1000 | 21 (32%) |
| >1000 | 1 (2%) |
| 2016 | |
| <1 | 1 (1%) |
| 1-10 | 14 (19%) |
| >10-100 | 31 (43%) |
| >100-1000 | 25 (35%) |
| >1000 | 1 (1%) |
| 2017 | |
| <1 | 4 (5%) |
| 1-10 | 16 (19%) |
| >10-100 | 37 (44%) |
| >100-1000 | 25 (29%) |
| >1000 | 3 (4%) |
| 2018 | |
| <1 | 2 (2%) |
| 1-10 | 15 (17%) |
| >10-100 | 38 (43%) |
| >100-1000 | 29 (33%) |
| >1000 | 5 (6%) |